MicroRNA-205-5p Inhibits Skin Cancer Cell Proliferation and Increase Drug Sensitivity by Targeting TNFAIP8

Overview

Journal Sci Rep

Specialty Science

Date 2021 Mar 12

PMID 33707587

Citations 5

Authors

Xinhong Ge

Suryakant Niture

Minghui Lin

Patrice Cagle

P Andy Li

Deepak Kumar

Affiliations

Soon will be listed here.

Abstract

Tumor necrosis factor-α-induced protein 8 (TNFAIP8) is a member of the TIPE/TNFAIP8 family which regulates tumor growth and survival. Our goal is to delineate the detailed oncogenic role of TNFAIP8 in skin cancer development and progression. Here we demonstrated that higher expression of TNFAIP8 is associated with basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma development in patient tissues. Induction of TNFAIP8 expression by TNFα or by ectopic expression of TNFAIP8 in SCC or melanoma cell lines resulted in increased cell growth/proliferation. Conversely, silencing of TNFAIP8 decreased cell survival/cell migration in skin cancer cells. We also showed that miR-205-5p targets the 3'UTR of TNFAIP8 and inhibits TNFAIP8 expression. Moreover, miR-205-5p downregulates TNFAIP8 mediated cellular autophagy, increased sensitivity towards the B-RAF mutant kinase inhibitor vemurafenib, and induced cell apoptosis in melanoma cells. Collectively our data indicate that miR-205-5p acts as a tumor suppressor in skin cancer by targeting TNFAIP8.

Citing Articles

miRNA signatures underlie chemoresistance in the gemcitabine-resistant pancreatic ductal adenocarcinoma cell line MIA PaCa-2 GR.

Fuller R, Vallejos P, Kabagwira J, Liu T, Wang C, Wall N Front Genet. 2024; 15:1393353.

PMID: 38919953 PMC: 11196613. DOI: 10.3389/fgene.2024.1393353.

microRNA-205 in prostate cancer: Overview to clinical translation.

Chauhan N, Manojkumar A, Jaggi M, Chauhan S, Yallapu M Biochim Biophys Acta Rev Cancer. 2022; 1877(6):188809.

PMID: 36191828 PMC: 9996811. DOI: 10.1016/j.bbcan.2022.188809.

Novel lncRNA SNHG16 Promotes the Growth and Metastasis of Malignant Melanoma by Regulating miR-205-5p/PAK2 Axis.

Xia Y, Guan J, Lu X, Liu Y, Luan W Clin Cosmet Investig Dermatol. 2022; 15:1615-1625.

PMID: 35983126 PMC: 9379127. DOI: 10.2147/CCID.S374404.

Exosomal miR-205-5p enhances angiogenesis and nasopharyngeal carcinoma metastasis by targeting .

Yang W, Tan S, Yang L, Chen X, Yang R, Oyang L Mol Ther Oncolytics. 2022; 24:612-623.

PMID: 35284624 PMC: 8892032. DOI: 10.1016/j.omto.2022.02.008.

MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.

Ghafouri-Fard S, Gholipour M, Taheri M Front Oncol. 2021; 11:608987.

PMID: 33968718 PMC: 8100681. DOI: 10.3389/fonc.2021.608987.

References

Sun H, Gong S, Carmody R, Hilliard A, Li L, Sun J . TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell. 2008; 133(3):415-26. PMC: 2398615. DOI: 10.1016/j.cell.2008.03.026. View

Rogers H, Weinstock M, Feldman S, Coldiron B . Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012. JAMA Dermatol. 2015; 151(10):1081-6. DOI: 10.1001/jamadermatol.2015.1187. View

Nguyen T, Kuo C, Nicholl M, Sim M, Turner R, Morton D . Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics. 2010; 6(3):388-94. PMC: 3063331. DOI: 10.4161/epi.6.3.14056. View

Chapman P, Hauschild A, Robert C, Haanen J, Ascierto P, Larkin J . Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507-16. PMC: 3549296. DOI: 10.1056/NEJMoa1103782. View

Mansouri B, Housewright C . The Treatment of Actinic Keratoses-The Rule Rather Than the Exception. JAMA Dermatol. 2017; 153(11):1200. DOI: 10.1001/jamadermatol.2017.3395. View

Bhatty M, Kato S, Piha-Paul S, Naing A, Subbiah V, Huang H . Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2018; 125(3):463-472. PMC: 6340722. DOI: 10.1002/cncr.31812. View

Lin K, Baritaki S, Militello L, Malaponte G, Bevelacqua Y, Bonavida B . The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit. Genes Cancer. 2010; 1(5):409-420. PMC: 2933925. DOI: 10.1177/1947601910373795. View

Lowe J, Nguyen T, Grimm S, Gabor K, Peddada S, Li L . The novel p53 target TNFAIP8 variant 2 is increased in cancer and offsets p53-dependent tumor suppression. Cell Death Differ. 2016; 24(1):181-191. PMC: 5260499. DOI: 10.1038/cdd.2016.130. View

Freundt E, Bidere N, Lenardo M . A different TIPE of immune homeostasis. Cell. 2008; 133(3):401-2. PMC: 2750003. DOI: 10.1016/j.cell.2008.04.017. View

10.

Kumar D, Whiteside T, Kasid U . Identification of a novel tumor necrosis factor-alpha-inducible gene, SCC-S2, containing the consensus sequence of a death effector domain of fas-associated death domain-like interleukin- 1beta-converting enzyme-inhibitory protein. J Biol Chem. 2000; 275(4):2973-8. DOI: 10.1074/jbc.275.4.2973. View

11.

Babapoor S, Wu R, Kozubek J, Auidi D, Grant-Kels J, Dadras S . Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing. Lab Invest. 2017; 97(6):636-648. DOI: 10.1038/labinvest.2017.5. View

12.

de Vries E, Coebergh J . Cutaneous malignant melanoma in Europe. Eur J Cancer. 2004; 40(16):2355-66. DOI: 10.1016/j.ejca.2004.06.003. View

13.

Gao H, Huo F, Wang H, Pei D . MicroRNA-9 inhibits the gastric cancer cell proliferation by targeting TNFAIP8. Cell Prolif. 2017; 50(2). PMC: 6529077. DOI: 10.1111/cpr.12331. View

14.

Sanchez-Sendra B, Martinez-Ciarpaglini C, Gonzalez-Munoz J, Murgui A, Terradez L, Monteagudo C . Downregulation of intratumoral expression of miR-205, miR-200c and miR-125b in primary human cutaneous melanomas predicts shorter survival. Sci Rep. 2018; 8(1):17076. PMC: 6244285. DOI: 10.1038/s41598-018-35317-3. View

15.

Yu H, Ma M, Yan J, Xu L, Yu J, Dai J . Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy. J Transl Med. 2017; 15(1):243. PMC: 5716227. DOI: 10.1186/s12967-017-1344-z. View

16.

Niture S, Moore J, Kumar D . TNFAIP8: Inflammation, Immunity and Human Diseases. J Cell Immunol. 2019; 1(2):29-34. PMC: 6853632. View

17.

Tang L, Wang K . Chronic Inflammation in Skin Malignancies. J Mol Signal. 2019; 11:2. PMC: 4911907. DOI: 10.5334/1750-2187-11-2. View

18.

Ahn J, Han B, Lee M . Induction of Resistance to BRAF Inhibitor Is Associated with the Inability of Spry2 to Inhibit BRAF-V600E Activity in BRAF Mutant Cells. Biomol Ther (Seoul). 2015; 23(4):320-6. PMC: 4489825. DOI: 10.4062/biomolther.2015.007. View

19.

Dar A, Majid S, de Semir D, Nosrati M, Bezrookove V, Kashani-Sabet M . miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J Biol Chem. 2011; 286(19):16606-14. PMC: 3089503. DOI: 10.1074/jbc.M111.227611. View

20.

Streicher K, Zhu W, Lehmann K, Georgantas R, Morehouse C, Brohawn P . A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth. Oncogene. 2011; 31(12):1558-70. DOI: 10.1038/onc.2011.345. View